Compositions and methods for administration of vaccines against dengue virus
Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.
1. A method for inducing an immune response in a subject against all four dengue virus serotypes, comprising,
administering to the subject by at least a first introduction, an immunogenic composition of a mixture comprising components of all four dengue virus serotypes, the composition comprising at least one live, attenuated dengue chimera comprising dengue-2/1, dengue-2/3 and dengue-2/4; and at least a non-chimera live, attenuated dengue-2 virus, and administering at least a second introduction of the immunogenic composition within 30 days of but not on the same day as, the first introduction to the subject and inducing an immune response in the subject against all four dengue virus serotypes.
2. The method of claim 1 , wherein administering the at least a second introduction occurs at a separate anatomical site on the subject as the first introduction.
3. The method of claim 1 , wherein the all four dengue virus serotypes are represented at a predetermined ratio in the immunogenic composition.
4. The method of claim 1 , further comprising administering at least one additional immunogenic agent against dengue virus to the subject as part of or separately from, the first immunogenic composition.
5. The method of claim 4 , wherein the additional immunogenic agent comprises at least one Toll receptor (TLR) ligand(s) and the additional immunogenic agent is added to the first immunogenic composition prior to administration to the subject.
6. The method of claim 1 , wherein the mixture of the four dengue virus serotypes comprises a live, attenuated dengue-2 virus, and at least one live, attenuated dengue chimera wherein capsid and non-structural proteins are from the live, attenuated dengue-2 virus, and wherein the backbone of the dengue chimera is dengue-2; and pre-membrane and envelope proteins are from at least a second, different dengue virus serotype.
7. The method of claim 6 , wherein the pre-membrane and envelope proteins of the at least a second dengue virus are from dengue-1, dengue-3 or dengue-4.
8. The method of claim 6 , wherein the at least one live, attenuated dengue chimeras are two or more of dengue-2/dengue-1, dengue-2/dengue-3 and dengue-2/dengue-4.
9. The method of claim 6 , wherein the live, attenuated dengue-2 virus concentration is reduced compared to the at least one dengue chimera in the immunogenic composition.
10. A method for inducing an immune response in a subject against dengue virus serotypes, comprising,
administering to the subject by a first introduction, a first immunogenic composition of four live, attenuated dengue viruses wherein the first immunogenic composition comprises live, attenuated dengue-2 virus wherein the live, attenuated dengue-2 virus is not chimeric; and three dengue chimeras of live, attenuated dengue viruses of dengue-2/1, dengue-2/3 and dengue-2/4; administering a second introduction of the first immunogenic composition within 30 days but not on the same day of administration of the first introduction and inducing an immune response in the subject against all four dengue virus serotypes.
11. The method of claim 10 , administering at least a second immunogenic composition in the same anatomical area as the first introduction.
12. The method of claim 10 , administering at least a second immunogenic composition at a separate anatomical area on the subject from the first introduction.
13. The method of claim 10 , wherein the four dengue virus serotypes of the first immunogenic composition comprise a predetermined ratio of one dengue virus serotype to another dengue virus serotype in the first immunogenic composition.
14. The method of claim 13 , wherein the live, attenuated dengue-2 virus concentration is reduced compared to the at least one dengue chimera in the immunogenic composition.
15. The method of claim 1 , wherein the immunogenic composition is administered to the subject by intradermal or subcutaneous administration.